期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 172, 期 1, 页码 1-23出版社
WILEY
DOI: 10.1111/bph.12906
关键词
-
资金
- Canadian Institutes of Health Research (CIHR) [NSA 93798]
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- F. Hoffmann - La Roche, Ltd. (Basel, Switzerland)
- St. Petersburg State University (St. Petersburg, Russia) [1.38.201.2014]
The variety of physiological functions controlled by dopamine in the brain and periphery is mediated by the D-1, D-2, D-3, D-4 and D-5 dopamine GPCRs. Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease. Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-associated behaviours and functions. Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as -arrestins that are classically involved in GPCR desensitization. Another level of complexity is the growing appreciation of the physiological roles played by dopamine receptor heteromers. Applications of new in vivo techniques have significantly furthered the understanding of the physiological functions played by dopamine receptors. Here we provide an update of the current knowledge regarding the complex biology, signalling, physiology and pharmacology of dopamine receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据